UCB's chief
executive officer (CEO) Roch Doliveux has been chosen as the chairman of the
governing board of Europe's Innovative Medicines Initiative (IMI).
The IMI is a public-private partnership between the EU and the European Federation of Pharmaceutical Industries and Associations, which UCB has been a part of since its inception.
It currently funds 30 projects covering areas such as drug safety and efficacy, knowledge management and education, providing a combined budget of around 600 million euros (501.62 million pounds).
Mr Doliveux, who has been part of the IMI governing board since May 2010, will help the organisation to further its aim of promoting greater collaboration within the healthcare sector.
"The biopharmaceutical industry has reached an inflection point where public-private partnerships, bringing academic and industry knowledge together, are paving the way to better respond to new healthcare needs," he said.
Earlier this month, the company reported its financial results for 2011, announcing an annual revenue total of 3.25 billion euros.
The IMI is a public-private partnership between the EU and the European Federation of Pharmaceutical Industries and Associations, which UCB has been a part of since its inception.
It currently funds 30 projects covering areas such as drug safety and efficacy, knowledge management and education, providing a combined budget of around 600 million euros (501.62 million pounds).
Mr Doliveux, who has been part of the IMI governing board since May 2010, will help the organisation to further its aim of promoting greater collaboration within the healthcare sector.
"The biopharmaceutical industry has reached an inflection point where public-private partnerships, bringing academic and industry knowledge together, are paving the way to better respond to new healthcare needs," he said.
Earlier this month, the company reported its financial results for 2011, announcing an annual revenue total of 3.25 billion euros.